ecteinascidin 743 has been researched along with sirolimus in 8 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | ecteinascidin 743 (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Myers, AG; Plowright, AT; Schaus, SE | 1 |
| von Mehren, M | 2 |
| Bailly, C | 1 |
| Monneret, C | 1 |
| Hayashi, M; Hisamatsu, T; Kawase, C; Kimura, T; Kurachi, H; Mabuchi, S; Mimura, K; Sawada, K; Takahashi, K; Takahashi, T | 1 |
| Hamasaki, T; Hisamatsu, T; Kawano, M; Kimura, T; Kishimoto, T; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, K; Takahashi, R; Takahashi, T | 1 |
2 review(s) available for ecteinascidin 743 and sirolimus
| Article | Year |
|---|---|
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
[Current impact of natural products in the discovery of anticancer drugs].
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bioengineering; Biological Products; Clinical Trials as Topic; Combinatorial Chemistry Techniques; Dioxoles; Drug Approval; Drug Discovery; Drug Screening Assays, Antitumor; Drugs, Investigational; Epothilones; Everolimus; Gemtuzumab; Humans; Immunoconjugates; Maytansine; Sirolimus; Tetrahydroisoquinolines; Trabectedin; United States; United States Food and Drug Administration; Vinblastine | 2010 |
6 other study(ies) available for ecteinascidin 743 and sirolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Transcriptional response pathways in a yeast strain sensitive to saframycin a and a more potent analog: evidence for a common basis of activity.
Topics: Acetyl Coenzyme A; Dioxoles; DNA Damage; DNA, Fungal; Fatty Acids; Fungal Proteins; Gene Expression Profiling; Gene Expression Regulation, Fungal; Genome, Fungal; Humans; Isoquinolines; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Quinolines; Saccharomyces cerevisiae; Sirolimus; Structure-Activity Relationship; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
New therapeutics for soft-tissue sarcomas in adults.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dioxoles; Enzyme Inhibitors; Humans; Protein Kinases; Protein-Tyrosine Kinases; Sarcoma; Sirolimus; Tetrahydroisoquinolines; Thalidomide; TOR Serine-Threonine Kinases; Trabectedin; Vascular Endothelial Growth Factor A | 2007 |
Ready for a comeback of natural products in oncology.
Topics: Antineoplastic Agents; Biological Products; Dioxoles; Epothilones; Humans; Neoplasms; Sirolimus; Tetrahydroisoquinolines; Trabectedin | 2009 |
The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dioxoles; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin; Xenograft Model Antitumor Assays | 2011 |
Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Cisplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Sirolimus; Tetrahydroisoquinolines; Topotecan; Trabectedin; Tumor Cells, Cultured | 2014 |